Product Images Rivastigmine Transdermal System

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 18 images provide visual information about the product associated with Rivastigmine Transdermal System NDC 63629-8807 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label - lbl636298807

Label - lbl636298807

This is a pharmaceutical product called NILD which contains 9.5 mg of Rivastigmine and is meant to be used as a Transdermal System. Each package has 30 systems and should be stored at a temperature range of 15° to 30°C. Users are advised to only use one patch at a time and not to cut it. Children should be kept away from this product. The NDC code for this product is 63629-8807-1.*

Chemical Structure - rivastigmine 01

Chemical Structure - rivastigmine 01

Figure 1 - rivastigmine 02

Figure 1 - rivastigmine 02

Figure 2 - rivastigmine 03

Figure 2 - rivastigmine 03

This text represents data on levels of the drug Rivastigmine in ng/mL for three different dosages (13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours) and their corresponding sample sizes (n = 19, n = 22, n = 22, respectively).*

Figure 3 - rivastigmine 04

Figure 3 - rivastigmine 04

Figure 4 - rivastigmine 05

Figure 4 - rivastigmine 05

Figure 5 - rivastigmine 06

Figure 5 - rivastigmine 06

Figure 6 - rivastigmine 07

Figure 6 - rivastigmine 07

Figure 7 - rivastigmine 08

Figure 7 - rivastigmine 08

The text appears to be a statistical analysis of a medication named Rivastigmine Transdermal System, with results indicating an improvement over 8, 16, and 24 weeks of treatment. The analysis presents LS means, STE, and statistical significance (p-values) at different time points. The medication comes in two doses - 15 cm² and 5cm².*

Figure 8 - rivastigmine 09

Figure 8 - rivastigmine 09

This is a description of a clinical trial for the Rivastigmine Transdermal System. The text provides LS means and standard errors obtained after 8, 16 and 24 weeks of treatment. The effect of the two different dosages (15 cm? and 5 cm?) is compared using statistical significance at a level of 0.05.*

Figure A - rivastigmine 10

Figure A - rivastigmine 10

Figure B - rivastigmine 11

Figure B - rivastigmine 11

This appears to be a list of body parts where a measurement or assessment can be taken, including the upper arm, side of chest, upper and lower back. However, the meaning of "LENGE," "Z," and "Lk" is not clear and may not be relevant.*

Figure C - rivastigmine 12

Figure C - rivastigmine 12

Figure D - rivastigmine 13

Figure D - rivastigmine 13

Figure E - rivastigmine 14

Figure E - rivastigmine 14

Figure F - rivastigmine 15

Figure F - rivastigmine 15

Figure G - rivastigmine 16

Figure G - rivastigmine 16

Figure H - rivastigmine 17

Figure H - rivastigmine 17

This seems to be a warning or instruction on how to dispose of a certain type of patch. It advises to fold the sticky sides together and place it in a trash or an empty pouch, which should be saved in order to keep it away from children and pets. It is not clear what the patch is specifically for or what type of patch it is.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.